Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of MBL949 in Obese Participants
NCT05199090Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2022
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MBL949 in obesity (6 arms), sponsored by Novartis. Primary endpoints: Frequency and Severity of Adverse Events and Change-from-baseline in Weight at Week 16. Started Feb 2022; status: terminated.
02
Drugs
MBL949
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05199090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05199090.